Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Huntington’s Disease Treatment Market Outlook

The global Huntington’s disease treatment market was estimated to be worth USD 446.08 million in 2023 and is likely to grow at a rate of 16% during the forecast period of 2024-2032. Driven by the growing demand and increasing R&D activities, the market is likely to attain a value of about USD 1,696.42 million by 2032.

huntingtons disease treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Huntington’s Disease Treatment Market: Introduction

The global Huntington's disease treatment market report by Expert Market Research provides an in-depth analysis of the market and its segments. Huntington's disease is a rare, inherited neurodegenerative disorder that affects a small percentage of the global population. The lack of effective treatments for Huntington's disease has been a major challenge for healthcare providers and researchers worldwide. The report covers the market for Huntington's disease treatment and provides a detailed analysis of the market size, growth, and trends.

The Huntington's disease treatment market is expected to witness significant advancements in the coming years. The development of novel therapies, such as gene therapy and RNA interference, and the increasing focus on personalized medicine are likely to drive the growth of the market. Additionally, the expansion of healthcare infrastructure in emerging economies and the increasing demand for advanced diagnostic tools and treatment options are expected to create lucrative opportunities for the market players.

Moreover, the growing adoption of telemedicine and digital health technologies may provide new avenues for the management and treatment of Huntington's disease, potentially improving patient outcomes and reducing healthcare costs. As a result, the global Huntington's disease treatment market is expected to continue its growth trajectory throughout the forecast period, offering numerous opportunities for key players and investors in the industry.

Huntington’s Disease Epidemiology

Huntington's disease is a rare inherited disorder that affects the brain and nervous system. The disease is caused by a genetic mutation that leads to the progressive breakdown of nerve cells in the brain. Huntington's disease affects people of all races and ethnicities, with an estimated prevalence of 5-10 cases per 100,000 people worldwide.

The onset of Huntington's disease typically occurs in midlife, with symptoms appearing between the ages of 30 and 50 years. The disease is characterized by a progressive loss of motor control, cognitive decline, and psychiatric symptoms. Currently, there is no cure for Huntington's disease, and the available treatments only provide symptomatic relief.

The prevalence of Huntington's disease varies across different regions of the world. The disease is more common in certain populations, such as those of European ancestry, and less common in others, such as those of Asian and African descent. In North America and Europe, the prevalence of Huntington's disease is estimated to be between 5 and 10 cases per 100,000 people, while in Asia and Africa, the prevalence is lower, at around 1 case per 100,000 people.

The incidence of Huntington's disease is also influenced by gender, with men and women being affected at similar rates. However, the age of onset may be slightly earlier in men than in women.

Huntington’s Disease Treatment Market Segmentations

The market can be categorised into treatment method, diagnosis method, drug class, treatment channel, and major region.

huntingtons disease treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Treatment Method

  • Symptomatic Treatment
  • Disease-modifying Therapies
  • Palliative Care Treatment
  • Others

Market Breakup by Diagnosis Method

  • Neurological Exams and Neuropsychological Tests
  • Psychiatric Evaluation
  • Brain-Imaging and Function Tests
  • Genetic Counselling
  • Predictive Genetic Tests
  • Others

Market Breakup by Drug Class

  • Mood Stabilizers
  • Antipsychotic Drugs
  • Antidepressants
  • Others

Market Breakup by Treatment Channel

  • Public
  • Private

Huntington’s Disease Treatment Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

huntingtons disease treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Huntington’s Disease Treatment Market Scenario

North America dominates the Huntington's disease treatment market, followed by Europe and the Asia Pacific. The high prevalence of Huntington's disease in North America and Europe, coupled with the favorable reimbursement policies, is driving the growth of the market in these regions. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about Huntington's disease and the rising healthcare expenditure in the region.

The market is highly fragmented, with numerous small and mid-sized companies operating in the market. The lack of effective treatments for Huntington's disease has led to the emergence of a large number of companies focusing on the development of innovative therapies for this disorder.

Key Players in the Global Huntington’s Disease Treatment Market

The report gives an in-depth analysis of the key players involved in the Huntington’s Disease Treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

  • H. Lundbeck A/S
  • Teva Pharmaceutical Industries Ltd.
  • Bausch Health Companies Inc.
  • Hetero Drugs Limited
  • Lupin Limited
  • Hikma Pharmaceuticals plc
  • Dr Reddy’s Laboratories Ltd
  • Sun Pharmaceutical Industries Limited
  • SOM Biotech
  • Annexon, Inc.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Treatment Method
  • Diagnosis Method
  • Drug Class
  • Treatment Channel
  • Region
Breakup by Treatment Method
  • Symptomatic Treatment
  • Disease-modifying Therapies
  • Palliative Care Treatment
  • Others
Breakup by Diagnosis Method
  • Neurological & Neuropsychological Tests
  • Psychiatric Evaluation
  • Brain-Imaging and Function Tests
  • Genetic Counselling
  • Predictive Genetic Tests
  • Others
Breakup by Drug Class
  • Mood Stabilizers
  • Antipsychotic Drugs
  • Antidepressants
  • Others
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
  • Industry Events, Initiatives & Trends
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • H. Lundbeck A/S
  • Teva Pharmaceutical Industries Ltd.
  • Bausch Health Companies Inc.
  • Hetero Drugs Limited
  • Lupin Limited
  • Hikma Pharmaceuticals plc
  • Dr. Reddy’s Laboratories Ltd
  • Sun Pharmaceutical Industries Limited
  • SOM Biotech
  • Annexon, Inc.

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market attained a value of about USD 446.08 million in 2023.

The market is likely to grow at a rate of 16% during the forecast period of 2024-2032 to attain a value of USD 1,696.42 million by 2032.

The market is primarily driven by the rising cases of Huntington’s disease, increasing research and developmental activities and novel product launches and approvals.

Based on the drug class, the market is categorised into mood stabilizers, antipsychotic drugs, antidepressants, and others.

Based on the diagnosis method, the market is segmented into neurological exams and neuropsychological tests, psychiatric evaluation, brain-imaging and function tests, genetic counselling, predictive genetic tests, and others.

Based on the treatment method, the market is bifurcated into symptomatic treatment, disease-modifying therapies, and palliative care treatment, among others.

Based on the treatment channel, the market is divided into public and private.

The different regions in the market are North America, Europe, Asia Pacific, Latin America the Middle East and Africa. North America is anticipated to hold a largest share of the market during the forecast period.

The key companies involved in the market are H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Hetero Drugs Limited, Lupin Limited, Hikma Pharmaceuticals plc, Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Limited, SOM Biotech, and Annexon, Inc., among others.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124